Cytarabine Dose for Acute Myeloid Leukemia REPLY

被引：0
|
作者：
Lowenberg, Bob [1 ]
机构：
[1] Erasmus Univ, Med Ctr, Rotterdam, Netherlands
来源：
NEW ENGLAND JOURNAL OF MEDICINE | 2011年 / 364卷 / 22期
关键词：
CHEMOTHERAPY; THERAPY; INDUCTION; ADULTS;
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：2168 / 2169
页数：2
相关论文
共 50 条
  • [41] Comparison of consolidation strategies in acute myeloid leukemia: high-dose cytarabine alone versus intermediate-dose cytarabine combined with anthracyclines
    Dae Sik Kim
    Ka-Won Kang
    Se Ryeon Lee
    Yong Park
    Hwa Jung Sung
    Seok Jin Kim
    Chul Won Choi
    Byung Soo Kim
    Annals of Hematology, 2015, 94 : 1485 - 1492
  • [42] Autophagy is an important event for low-dose cytarabine treatment in acute myeloid leukemia cells
    Chen, Liyun
    Guo, Pei
    Zhang, Yunxiang
    Li, Xiaoyang
    Jia, Peimin
    Tong, Jianhua
    Li, Junmin
    LEUKEMIA RESEARCH, 2017, 60 : 44 - 52
  • [43] Pharmacological study of modified intermediate-dose cytarabine therapy in patients with acute myeloid leukemia
    Sutoh, H
    Yamauchi, T
    Gotoh, N
    Sugiyama, M
    Ueda, T
    ANTICANCER RESEARCH, 2003, 23 (6D) : 5037 - 5042
  • [44] Low dose cytarabine with or without anthracycline in the induction treatment of elderly patients with acute myeloid leukemia
    Abu-Taleb, F. M.
    Mansour, O. M.
    Khorshid, O. L. A. M. R.
    Raheem, A. Abdel
    EUROPEAN JOURNAL OF CANCER, 2013, 49 : S850 - S850
  • [45] Continuous drip infusion therapy of low dose cytarabine and etoposide for hypoplastic acute myeloid leukemia
    Yamada, T
    Tsurumi, H
    Sawada, M
    Kasahara, S
    Hara, T
    Fukuno, K
    Kanemura, N
    Goto, H
    Oyama, M
    Moriwaki, H
    BLOOD, 2002, 100 (11) : 261B - 261B
  • [46] Genetics as predictive marker for consolidation therapy with high-dose cytarabine in acute myeloid leukemia
    Schlenk, Richard F.
    HAEMATOLOGICA, 2024, 109 (06) : 1629 - 1630
  • [47] Is Intermediate-Dose Cytarabine a Good Control for Patients with Relapsed or Refractory Acute Myeloid Leukemia?
    Bertoli, Sarah
    Gadaud, Noemie
    Tavitian, Suzanne
    Sarry, Audrey
    Berard, Emilie
    Huguet, Francoise
    Recher, Christian
    BLOOD, 2016, 128 (22)
  • [48] Efficacy and safety of consolidation therapy with intermediate and high dose cytarabine in acute myeloid leukemia patients
    Tangchitpianvit, Kittisak
    Rattarittamrong, Ekarat
    Chai-Adisaksopha, Chatree
    Piriyakhuntorn, Pokpong
    Rattanathammethee, Thanawat
    Hantrakool, Sasinee
    Tantiworawit, Adisak
    Norasetthada, Lalita
    HEMATOLOGY, 2021, 26 (01) : 355 - 364
  • [49] Venetoclax in combination with hypomethylating agents or low dose cytarabine for relapsed and refractory acute myeloid leukemia
    Graveno, Molly E.
    Carulli, Alison
    Freyer, Craig W.
    Mangan, Brendan L.
    Nietupski, Robert
    Loren, Alison W.
    Frey, Noelle, V
    Porter, David L.
    Gill, Saar, I
    Hexner, Elizabeth O.
    Luger, Selina M.
    Martin, Mary Ellen
    McCurdy, Shannon R.
    Perl, Alexander E.
    Babushok, Daria, V
    Pratz, Keith W.
    LEUKEMIA & LYMPHOMA, 2022, 63 (07) : 1645 - 1650
  • [50] More options for older patients with acute myeloid leukemia: venetoclax in combination with low dose cytarabine
    Aldoss, Ibrahim
    Marcucci, Guido
    CHINESE CLINICAL ONCOLOGY, 2019, 8
12345